Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESCUE-2: Ziltivekimab for inflammation reduction in advanced chronic kidney disease (Japan)
jRCT2031200216Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ziltivekimab in chronic kidney disease (CKD), chronic inflammation and atherosclerotic disease (3 arms), sponsored by Novo Nordisk. Started Oct 2020; status: completed.
02
Drugs
ziltivekimab
03
Conditions
chronic kidney disease (CKD)chronic inflammationatherosclerotic disease
Beyond the preview
Go deeper on jRCT2031200216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200216.